Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 10/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28073211 | 1.00 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3CA12CA1 | |
| SCHEMBL28073280 | 0.94 | SLC6A2 (0.38) | SLC6A2SLC6A4SLC6A3CA12CA1 | |
| SCHEMBL28621836 | 0.87 | SLC6A2 (0.34) | SLC6A2SLC6A4SLC6A3CA12CA1 | |
| SCHEMBL27923441 | 0.87 | SLC6A2 (0.34) | SLC6A2SLC6A4SLC6A3CA12CA1 | |
| SCHEMBL28624969 | 0.84 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3CA12CA1 | |
| SCHEMBL1700229 | 0.83 | CA2 (0.41) | SLC6A2SLC6A4CA12CA1CA2 | |
| SCHEMBL1700302 | 0.83 | CA2 (0.41) | SLC6A2SLC6A4CA12CA1CA2 | |
| SCHEMBL1700230 | 0.83 | CA2 (0.41) | SLC6A2SLC6A4CA12CA1CA2 | |
| SCHEMBL27935392 | 0.82 | CA12 (0.33) | SLC6A2SLC6A4SLC6A3CA12CA1 | |
| SCHEMBL27893509 | 0.80 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3CA2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109897038-B | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | 艾伯维爱尔兰无限公司 | 2022-04-05 | — | — | CN | disclosed |
| CN-108175749-B | Melt-extruded solid dispersions containing apoptosis-inducing agents | 艾伯维爱尔兰无限公司 | 2021-09-10 | — | — | CN | disclosed |
| CN-109966294-A | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | 艾伯维爱尔兰无限公司 | 2019-07-05 | — | — | CN | disclosed |
| CN-109897038-A | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | 艾伯维爱尔兰无限公司 | 2019-06-18 | — | — | CN | disclosed |
| CN-106008466-B | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | 艾伯维公司 | 2018-12-14 | — | — | CN | disclosed |
| CN-106008322-B | sulfonamide derivatives as BC L-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases | ABBVIE 公司 | 2018-09-04 | — | — | CN | disclosed |
| CN-108175749-A | The solid dispersions of melt extrusion containing cell death inducer | 艾伯维爱尔兰无限公司 | 2018-06-19 | — | — | CN | disclosed |
| CN-103282025-B | Melt-extruded solid dispersions containing apoptosis-inducing agents | 艾伯维爱尔兰无限公司 | 2018-01-02 | — | — | CN | disclosed |
| CN-106397418-A | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE公司 | 2017-02-15 | — | — | CN | disclosed |
| CN-103167867-B | Solid dispersion containing apoptosis-inducing medicament | ABBVIE 公司 | 2016-12-21 | — | — | CN | disclosed |
| CN-106008322-A | BCL-2-selectively apoptosis-inducing agents for the treatment of cancer and immune diseases | ABBVIE 公司 | 2016-10-12 | — | — | CN | disclosed |
| CN-106008466-A | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | 艾伯维公司 | 2016-10-12 | — | — | CN | disclosed |
| CN-102307622-B | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | 艾伯维公司 | 2016-08-17 | — | — | CN | disclosed |
| CN-103153993-B | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (BS) | 2016-06-01 | — | — | CN | disclosed |